Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clobazam
Drug ID BADD_D00488
Description Clobazam belongs to the 1,5-benzodiazepine class of drugs and is expected to have a better side-effect profile compared to older 1,4-benzodiazepines. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. The oral preparation was FDA approved on October 21, 2011. An oral suspension is expected to be available in 2013.
Indications and Usage For treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy.
Marketing Status Prescription; Discontinued
ATC Code N05BA09
DrugBank ID DB00349
KEGG ID D01253
MeSH ID D000078306
PubChem ID 2789
TTD Drug ID D0S9MC
NDC Product Code 67386-313; 64330-110; 69766-016; 51672-4203; 0054-0561; 11014-0115; 82348-103; 72606-003; 69452-115; 42571-316; 67877-666; 51672-4210; 70710-1326; 51672-4202; 68180-157; 16714-087; 69238-1305; 51672-4227; 67877-665; 11014-0114; 69037-0009; 13632-313; 66689-058; 59651-401; 69238-1535; 0832-0585; 65085-0054; 70771-1441; 70710-1325; 47621-047; 67877-658; 69539-153; 67386-314; 68180-156; 0527-1681; 60687-423; 12828-0084; 68180-158; 31722-639; 31722-640; 10094-205; 69539-154; 70771-1440; 0832-0581; 16714-887; 72606-004; 0378-8043; 0832-0580; 42571-315; 69452-114; 0781-8013; 0054-0526; 51991-900; 51991-901; 42571-308; 0527-1682; 48087-0094; 10094-210; 0527-5301; 69238-1306; 69452-116; 16714-888; 67386-315; 0781-8014; 10094-220; 31722-641; 0054-0527; 48087-0117
Synonyms Clobazam | Urbanyl | Onfi | 1-Phenyl-5-methyl-8-chloro-1,2,4,5- tetrahydro-2,4-diketo-3H-1,5-benzodiazepine | HR 376 | LM-2717 | LM 2717 | LM2717 | Frisium
Chemical Information
Molecular Formula C16H13ClN2O2
CAS Registry Number 22316-47-8
SMILES CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver function test abnormal13.03.01.013--Not Available
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.003--Not Available
Lung disorder22.02.07.0010.000602%Not Available
Malaise08.01.01.003--
Memory impairment19.20.01.003; 17.03.02.003--
Mental impairment19.21.02.003; 17.03.03.0020.000602%Not Available
Mood altered19.04.02.0070.007826%Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.0050.001505%Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myoclonus17.02.05.0080.000903%Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.002408%
Osteoarthritis15.01.04.001--Not Available
Pancreatitis07.18.01.0010.000903%
Paranoia19.05.01.0050.000602%Not Available
Petit mal epilepsy17.12.04.0010.001204%Not Available
Pneumonia22.07.01.003; 11.01.09.0030.005418%Not Available
Pneumonia aspiration22.01.01.0050.000550%Not Available
Premature delivery18.07.01.0060.000602%
Prothrombin time shortened13.01.02.0130.000602%Not Available
Pruritus23.03.12.001--
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.001806%Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages